On October 24, 2016, pembrolizumab received approval as first-line treatment for metastatic NSCLC with ≥50% PD-L1 expression and without EGFR or ALK genomic tumor aberrations [25]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.